Skip to main content
Download PDF

Volume 11 Supplement 2

Proceedings of 20th Pediatric Rheumatology European Society (PReS) Congress

PReS13-SPK-1587: New biologic targets for the future and basic science behind them

Pediatric Rheumatology volume 11, Article number: I17 (2013) Cite this article

The treatment of paediatric rheumatic diseases has made great progress in the last decade. The introduction of the biologicals meant (after the introduction of MTX) the second therapeutic revolution. This together with many improvements in related areas has greatly improved the quality of life of patients with rheumatic diseases. At present however, despite the introduction of more biological agents directed at immune targets the progression has stalled. The next challenge will be to:

1) Better understand the immune pathogenesis underlying the heterogeneity of the disease.

2) Identify patients at risk at the onset of disease and stratify them according to risk factors.

3) Personalize treatment based on their risk profiling.

4) Develop strategies that are aimed not only at suppressing disease but also at maintaining disease remission after withdrawing immune suprresion.

Over the last years much progress has been made in all these area's. In this presentation we will discuss this progress, focusing on a better understanding of the mechanisms of immune tolerance, leading to new targets for intervention.

Disclosure of interest

B. Prakken Grant/Research Support from: Dutch Arthritis Foundation.

References

  1. Zonneveld-Huijssoon E, et al: TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis. Annals of the rheumatic diseases. 2012, 71 (10): 1706-1715. 10.1136/annrheumdis-2011-201131.

    Article  CAS  PubMed  Google Scholar 

  2. Wehrens E, et al: T cells out of control-impaired immune regulation in the inflamed joint. Nature reviews. Rheumatology. 2012, doi:10.1038/nrrheum.2012.149

    Google Scholar 

  3. Albani S, et al: Induction of immune tolerance in the treatment of rheumatoid arthritis. Nature reviews. Rheumatology. 2011, 7 (5): 272-281. 10.1038/nrrheum.2011.36.

    Article  CAS  PubMed  Google Scholar 

  4. Prakken B, et al: Juvenile idiopathic arthritis. 2011, Lancet, 377 (9783): 2138-2149.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Immunology, University Medical Centre Utrecht, Utrecht, Netherlands

    B Prakken

Authors
  1. B Prakken
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Cite this article

Prakken, B. PReS13-SPK-1587: New biologic targets for the future and basic science behind them. Pediatr Rheumatol 11 (Suppl 2), I17 (2013). https://doi.org/10.1186/1546-0096-11-S2-I17

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1546-0096-11-S2-I17

Keywords

  • Public Health
  • Arthritis
  • Basic Science
  • Rheumatic Disease
  • Biological Agent

Pediatric Rheumatology

ISSN: 1546-0096